# A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Source: https://onco.cc/trials/nct05009329/  
OnCo record `nct05009329` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Glecirasib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China is a phase 1/2 interventional study registered as NCT05009329 by Allist Pharmaceuticals, Inc., with 315 participants enrolled, started 2021-07-26 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-21822.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05009329
- Phase: 1/2
- Setting: Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation
- Sponsor: Allist Pharmaceuticals, Inc.
- Enrolled: 315

## Sources

- ClinicalTrials.gov NCT05009329: https://clinicaltrials.gov/study/NCT05009329

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Glecirasib](https://onco.cc/drugs/glecirasib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)

---
JSON: https://onco.cc/api/v1/entities/nct05009329.json